Δημοσίευση

Glucose Levels Before the Onset of Asparaginase Predicts Transient Hyperglycemia in Children With Acute Lymphoblastic Leukemia.

ΤίτλοςGlucose Levels Before the Onset of Asparaginase Predicts Transient Hyperglycemia in Children With Acute Lymphoblastic Leukemia.
Publication TypeJournal Article
Year of Publication2016
AuthorsGatzioura, I., Papakonstantinou E., Dimitriadou M., Kourti M., Sidi V., Triantafyllou P., Koliouskas D., & Christoforidis A.
JournalPediatr Blood Cancer
Volume63
Issue7
Pagination1181-4
Date Published2016 07
ISSN1545-5017
Λέξεις κλειδιάAdolescent, Asparaginase, Blood Glucose, Child, Child, Preschool, Female, Humans, Hyperglycemia, Infant, Male, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Retrospective Studies, Risk Factors
Abstract

BACKGROUND: Transient hyperglycemia (TH) represents an acknowledged adverse event that occurs during treatment in children with acute lymphoblastic leukemia (ALL) and has recently been associated with an increased risk for developing metabolic disturbances in future life. Our aim was to estimate the incidence of TH and to identify risk factors, thus serving as markers for identifying candidates for prevention interventions.PROCEDURE: All patients treated with induction treatment for ALL in our department from January 2004 to April 2015 had their data retrieved from medical files and retrospectively analyzed.RESULTS: One hundred and two children with ALL treated at our department were identified (49 females and 53 males) with a mean age of 6.03 ± 3.78 years at the time of diagnosis. Sixteen patients developed TH (15.68%). Age at diagnosis >10 years is associated with an 11-fold increase in the risk of developing TH. Additionally, fasting glucose on the eighth day of treatment is an important prognostic factor as fasting glucose >100 mg/dl at that time point is associated with a threefold increase in developing TH during residual treatment period.CONCLUSIONS: Fasting glucose levels >110 mg/dl on the eighth day of treatment could serve as a trigger for intervention strategies that will prevent the development of TH in pediatric patients treated for ALL. Additional studies are needed to confirm and further extend this preliminary observation.

DOI10.1002/pbc.25956
Alternate JournalPediatr Blood Cancer
PubMed ID27062362

Επικοινωνία

Γραμματεία Τμήματος Ιατρικής T.K. 54124 Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα social networks.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.